- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05463120
Minidojrzewanie niemowlęce i czas dojrzewania w okresie dojrzewania: obserwacja kohorty karmienia niemowląt i wczesnego rozwoju (IFED)
Background:
Earlier puberty is associated with adverse health throughout a person s life. The average age when puberty begins has been declining over the past decades in girls, and may also be declining in boys. The reasons for this shift are unknown.
Objective:
To determine whether internal (physical, hormonal) or external (feeding, environment) factors during infancy affect growth and the timing of puberty.
Eligibility:
Mothers (or other parent/guardian) and their children who completed the Infant Feeding and Early Development (IFED) study.
Design:
Participants will complete all activities at home for this natural history study.
Participant mothers will fill out two 15-minute questionnaires:
- One will be about themselves. They will answer questions about their body size in childhood, their puberty, and their pregnancies.
- The other will be about their child. They will answer questions about their child s puberty and lifestyle.
Child participants will fill out a questionnaire about their body changes during puberty. This will take 10 minutes.
Participants will be sent an electronic scale and a measuring tape. They will measure the child s weight, height, and waist and hip circumference. These numbers can be submitted online or by phone or mail.
Participants will receive a kit for collecting urine samples. Child participants will collect urine in a cup upon waking 4 days in a row. A special filter card is dipped in the cup then hung to dry. The dried cards will be mailed back.
Participants will allow researchers to access their child s medical records.
Questionnaires and body measurements will be repeated after 6 and 12 months. Urine sample collection will be repeated after 12 months.
All questionnaires can be done either online, by mail, or by phone on request.
Przegląd badań
Status
Warunki
Szczegółowy opis
Study Description: Our overarching hypothesis is that endogenous and exogenous factors related to hypothalamic-pituitary-gonadal (HPG) axis activity during minipuberty of infancy are associated with childhood growth, the timing of pubertal development, and HPG axis activity in adolescence. To examine this hypothesis, we will conduct an observational follow-up study of children previously enrolled as infants in the Infant Feeding and Early Development (IFED) cohort. This follow-up study will be conducted remotely with data collection via email/online, mail and telephone by contractors at DLH, working on behalf of NIEHS.
Objectives: Primary Objective: To assess whether endogenous (e.g. hormone concentrations and size of hormone-sensitive organs) and exogenous (e.g. infant feeding method, exposure to endocrine disrupting chemicals) factors during minipuberty of infancy are related to a) growth, b) timing of pubertal development, and c) HPG axis activity in adolescence.
Endpoints: Primary Endpoints:
- Height, weight and body mass index (BMI)
- Onset of breast, pubic hair and/or genital development
- Urinary metabolites of reproductive hormones (e.g. gonadotropins and sex steroids)
Typ studiów
Zapisy (Szacowany)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Maryland
-
Bethesda, Maryland, Stany Zjednoczone, 20892
- National Institute of Environmental Health Sciences (NIEHS)
-
-
North Carolina
-
Durham, North Carolina, Stany Zjednoczone, 27703
- Social & Scientific Systems
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
The eligible population includes 283 children (136 girls, 147 boys), and their mothers or other parent/guardian, who completed the original IFED study, conducted when the children where 0-9 months of age (2010-2014).
Opis
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Completion of the original IFED study, defined as participants who did not withdraw from the study or were not withdrawn by the investigator prior to the end of original follow-up (up to 7 months in males and 9 months in females) and who provided at least the minimum number of blood samples (3 for boys, 4 for girls) across the original study period (N=283 eligible families).
- Ability of subject and mother to understand and the willingness to review informed assent and consent documents, respectively, and indicate agreement to participate.
EXCLUSION CRITERIA:
We will not exclude any participants that meet the inclusion criteria from participating in the study overall or in any of the study procedures. We will collect information, via maternal report and linked medical records, on relevant medical diagnoses and the use of medications that may affect hormone levels, growth, and pubertal development. We may exclude participants with reported conditions or medication use (listed below) from analyses of some study aims or in sensitivity analyses.
Diagnoses/conditions:
- Central or peripheral precocious puberty
- Delayed puberty
- Growth hormone deficiency
- Stunted or delayed growth
- Idiopathic short stature
- Hypopituitarism
- Thyroid conditions, such as hyperthyroid, hypothyroid, Graves disease, Hashimoto's thyroiditis
- Genetic conditions, such as Prader-Willi syndrome, Turner syndrome, and Noonan syndrome
Medications:
- Gonadotropin-Releasing Hormone Agonists (e.g., leuprolide acetate (Lupron Depot), triptorelin (Triptodur), histrelin implant (Supprelin LA))
- Hormone therapy (e.g., testosterone, estrogen)
- Synthetic human growth hormone or IGF-1
- Synthetic thyroid hormone (e.g., levothyroxine)
- Anti-thyroid medications (e.g., methimazole, propylthiouracil) or radioactive iodine treatment
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Kohorty i interwencje
Grupa / Kohorta |
|---|
|
IFED-2
Children who participated in the IFED study as infants (2010-2014) and a parent/guardian will be enrolled in this follow-up study in childhood and followed for at least one year. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
To assess whether growth, timing of pubertal development, and hypothalamic-pituitary-gonadal (HPG) axis activity in childhood and adolescence are related to endogenous and exogenous endocrine-related factors during minipuberty of infancy.
Ramy czasowe: Various time points in childhood/adolescence (study enrollment, 6-month and 12-month follow-up visits currently planned). We anticipate that children will be 8-12 years of age at enrollment (2022) and followed prospectively.
|
1)Growth in height, weight and body mass index 2)Onset of pubic hair development, breast development (females), genital development (males) 3)Urinary concentrations of reproductive hormone metabolites (e.g., gonadotropins, estradiol, testosterone) |
Various time points in childhood/adolescence (study enrollment, 6-month and 12-month follow-up visits currently planned). We anticipate that children will be 8-12 years of age at enrollment (2022) and followed prospectively.
|
Współpracownicy i badacze
Śledczy
- Główny śledczy: Dale P Sandler, Ph.D., National Institute of Environmental Health Sciences (NIEHS)
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Inne numery identyfikacyjne badania
- 10000945
- 000945-E
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Individual participant data may be shared with other researchers upon request. Plans for sharing data if requested are included in the study protocol.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .